Low Mortality in Fetal Supraventricular Tachycardia: Outcomes in a 30 ‐Year Single Institution Experience

ConclusionsFetuses with structurally normal hearts and sustained SVT can be effectively managed with transplacental drug therapy with minimal risk of intrauterine fetal demise. Treatment requires multiple anti ‐arrhythmic agents in over half of cases. Later gestational age at fetal diagnosis and the presence of depressed fetal ventricular function, but not hydrops, predict postnatal arrhythmia burden.This article is protected by copyright. All rights reserved.

Source: Journal of Cardiovascular Electrophysiology - February 28, 2020 Category: Cardiology Authors: Edward T. O'Leary, Mark E. Alexander, Vassilios J. Bezzerides, Monika Drogosz, Kathleen E. Economy, Kevin G. Friedman, Sarah S. Pickard, Wayne Tworetzky, Douglas Y. Mah Tags: ORIGINAL ARTICLE Source Type: research